PubMed Health⌕ Search

PubMed · 15446909

Vibronic coupling and double excitations in linear response time-dependent density functional calculations: dipole-allowed states of N2.

Abstract

The present study serves two purposes. First, we evaluate the ability of present time-dependent density functional response theory (TDDFRT) methods to deal with avoided crossings, i.e., vibronic coupling effects. In the second place, taking the vibronic coupling effects into account enables us, by comparison to the configuration analysis in a recent ab initio study [J. Chem. Phys. 115, 6438 (2001)], to identify the neglect of double excitations as the prime cause of limited accuracy of these linear response based TDDFRT calculations for specific states. The "statistical averaging of (model) orbital potentials (SAOP)" Kohn-Sham potential is used together with the standard adiabatic local-density approximation (ALDA) for the exchange-correlation kernel. We use the N2 molecule as prototype, since the TDDFRT/SAOP calculations have already been shown to be accurate for the vertical excitations, while this molecule has a well-studied, intricate vibronic structure as well as significant double excitation nature in the lowest 1Pi(u) state at elongated bond lengths. A simple diabatizing scheme is employed to obtain a diabatic potential energy matrix, from which we obtain the absorption spectrum of N2 including vibronic coupling effects. Considering the six lowest dipole allowed transitions of 1Sigma(u)+ and 1Pi(u) symmetry, we observe a good general agreement and conclude that avoided crossings and vibronic coupling can indeed be treated satisfactorily on the basis of TDDFRT excitation energies. However, there is one state for which the accuracy of TDDFRT/ALDA clearly breaks down. This is the state for which the ab initio calculations find significant double excitation character. To deal with double excitation character is an important challenge for time-dependent density functional theory.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Johannes Neugebauer, Evert Jan Baerends, Marcel Nooijen. 2004-10-01. Vibronic coupling and double excitations in linear response time-dependent density functional calculations: dipole-allowed states of N2.. https://doi.org/10.1063/1.1785775

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗